AbCellera's stock rose 7.2% after announcing sizable upfront payments from its new T cell engager (TCE) collaborations with Vertex and Jazz Pharmaceuticals, which added over $110 million in near-term cash and significant potential downstream revenue.
- Completed enrollment and initial dosing for the Phase II study of ABCL635 in menopause-related hot flashes, with data expected imminently.
- Advanced pipeline programs ABCL-688 and ABCL386 are expected to enter Phase I/II trials in 2027; ABCL575 Phase I dosing completed with readout due in Q4.
- Missed prior goal to move a program into IND-enabling activities in H1 but reported ongoing progress in discovery.
- Announced two new TCE collaborations: $28 million upfront from Vertex targeting autoimmune diseases, and $84 million upfront (with $56 million received) from Jazz, with potential total deal values exceeding $4 billion across five programs.
- Strong liquidity position with $565 million cash and equivalents plus $110 million of committed government funding to support strategic execution.
Community Discussion